Baclofen shows modest but real benefits for some people with alcohol use disorder, though the evidence is frustratingly inconsistent. A large Cochrane review found that baclofen probably reduces the risk of relapse and increases the number of alcohol-free days compared to placebo, yet several individual trials have failed to show clear advantages. The drug remains off-label for this purpose in nearly every country except France, and no one has settled on the right dose. That messy picture makes baclofen one of the more polarizing options in addiction medicine, with passionate advocates, cautious skeptics, and a patient population that sometimes responds dramatically when other treatments have failed.
How Baclofen Entered the Picture
Baclofen has been around since the 1960s as a muscle relaxant, primarily prescribed for spasticity in conditions like multiple sclerosis and spinal cord injuries. It works by activating GABA-B receptors in the brain, which dampen excitatory nerve signaling. The leap to alcohol treatment came from an unlikely source: Olivier Ameisen, a French-American cardiologist who struggled with severe alcohol dependence and, in desperation, began self-prescribing high doses of baclofen. He published his experience in a case report and later in a bestselling book, “Le Dernier Verre” (The Last Glass), around 2008.1Alcohol and Alcoholism. Baclofen and Alcohol Use Disorders: Breakthrough or Great White Elephant? His claim that baclofen had completely suppressed both his cravings and his anxiety generated enormous public interest, particularly in France, and triggered a wave of clinical trials that have been running ever since.
What the Strongest Evidence Says
The most comprehensive look at baclofen’s effectiveness comes from a Cochrane systematic review covering 16 randomized controlled trials and over 1,200 participants. The review found high-certainty evidence that baclofen increases the percentage of days people remain abstinent, with an average gain of about nine more abstinent days over the treatment period compared to placebo. It also found moderate-certainty evidence that baclofen probably reduces the risk of relapsing to any drinking by roughly 13 percent.2PubMed Central. Baclofen for alcohol use disorder Those numbers sound encouraging, and by the standards of addiction pharmacotherapy they are meaningful. But the same review found no clear benefit for reducing heavy drinking days, which is one of the outcomes that matters most to people trying to cut back rather than quit entirely.
It is worth noting that an earlier version of this same Cochrane review, based on fewer trials, had found no significant differences between baclofen and placebo on any primary outcome.3Cochrane Database of Systematic Reviews. Baclofen for alcohol use disorder The updated analysis, with more studies pooled, tipped several outcomes in baclofen’s favor. That trajectory suggests the effect is real but small enough that early trials were individually underpowered to detect it. It also means researchers who ran any single negative trial were not necessarily wrong to report one; the signal just was not loud enough to clear the noise in a sample of a few hundred people.
The Dose Problem
One of the biggest unresolved questions is how much baclofen a person needs. The approved dose for spasticity tops out around 80 milligrams per day. Many of the early alcohol trials used similarly low doses, typically 30 milligrams per day, and got underwhelming results. High-dose advocates, inspired by Ameisen’s self-treatment at doses exceeding 200 milligrams per day, pushed for trials at much higher levels.
Results from those high-dose trials have been split. The BACLAD study, a German trial using individually titrated doses up to 270 milligrams per day, found strikingly positive results: about 68 percent of baclofen patients stayed completely abstinent during the high-dose phase compared to roughly 24 percent on placebo, with no drug-related serious adverse events.4PubMed. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial But the study was small, with only 56 participants randomized. The much larger ALPADIR study, which enrolled 320 patients in France at a target dose of 180 milligrams per day, found no significant difference between baclofen and placebo for its primary endpoint of sustained abstinence, though it did observe a trend toward reduced alcohol consumption and a significant decrease in craving scores.5Alcohol and Alcoholism. A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients—The ALPADIR Study
A Dutch multicenter trial added further doubt: patients randomized to high-dose baclofen (up to 150 milligrams per day) showed no benefit over placebo or low-dose baclofen for time to first relapse, and side effects like fatigue, sleepiness, and dry mouth were common. Only about 16 percent of patients in the high-dose arm actually reached the target of 150 milligrams, with the average dose landing around 94 milligrams because side effects forced dose reductions.6European Neuropsychopharmacology. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial That poor tolerability at higher doses is a recurring theme and one reason some researchers have argued for flexible, individually tailored dosing rather than fixed high-dose protocols.
Who Benefits Most
The inconsistent trial results have driven researchers to look for subgroups that respond better than average. A few patterns have emerged, though none are definitive enough to serve as firm prescribing criteria.
People who drink more heavily at the start of treatment appear to get more out of baclofen. An analysis from the BacALD trial found that baclofen, regardless of dose, was more effective at delaying relapse when patients had higher baseline alcohol consumption. In that subgroup, the drug roughly halved the risk of lapsing back to drinking compared to placebo.7Alcohol and Alcoholism. Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial Other baseline characteristics, including age, sex, and psychiatric history, did not predict response in that study.
People with co-occurring anxiety may also respond disproportionately well. Baclofen’s GABA-B activity gives it inherent anti-anxiety properties, and a post hoc analysis from a three-arm trial found that in alcohol-dependent patients who also had a comorbid anxiety disorder, both 30 and 60 milligrams per day of baclofen delayed relapse compared to placebo.8Alcohol and Alcoholism. Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety A separate randomized trial similarly found a significant reduction in state anxiety among baclofen-treated patients.9Alcoholism: Clinical and Experimental Research. Efficacy and Safety of Baclofen for Alcohol Dependence: A Randomized, Double‐Blind, Placebo‐Controlled Trial Since anxiety and alcohol dependence frequently reinforce each other, a medication that addresses both could break that cycle for certain patients.
Baclofen and Liver Disease
This is where baclofen has carved out its clearest clinical niche. The two medications approved in the United States for alcohol use disorder, naltrexone and acamprosate, each have limitations in people with advanced liver disease. Naltrexone is processed through the liver and carries warnings about hepatotoxicity, making it a poor fit for patients with alcohol-related cirrhosis.10Surgery, Gastroenterology and Oncology. Baclofen versus Acamprosate for Maintainence of Alcohol Abstinence in Patients with Cirrhosis of Liver: A Double Blinded Randomized Trial Acamprosate is safer for the liver since it is cleared through the kidneys, but neither drug has been extensively studied in cirrhotic populations.
Baclofen, by contrast, is largely eliminated by the kidneys and has been studied specifically in patients with liver cirrhosis. A decade of evidence in this population shows it can reduce alcohol intake, promote abstinence, and prevent relapse, with an acceptable safety profile even in people with advanced liver disease.11PubMed Central. Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence Systematic reviews have also characterized baclofen as safe and well tolerated with low addiction potential in the setting of moderate-to-severe cirrhosis.12PubMed. Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence For patients whose liver is already damaged by alcohol, baclofen is often the only pharmacological option that clinicians feel comfortable prescribing, and recent international guidelines have begun to reflect that.
Safety Concerns and Side Effects
At lower doses, baclofen’s side-effect profile is generally mild: drowsiness, dizziness, and fatigue are the most common complaints. As doses climb, however, the picture changes. French pharmacovigilance data have identified mental confusion, mania, depression and suicidal behavior, psychosis, seizures, and sleep apnea as the most dangerous effects associated with baclofen use for alcohol use disorder.13Alcohol and Alcoholism. Baclofen in the treatment of alcohol use disorder: tailored doses matter These serious complications are rare at standard doses but become a real concern above 80 to 120 milligrams per day, especially in patients taking other central nervous system depressants.
The interaction between baclofen and alcohol itself deserves attention. Both substances depress the central nervous system, and combining them can amplify respiratory depression.14PubMed. Baclofen (fun drug) and ethanol combined poisoning in humans: A histopathology and morphometry model This creates a paradox for prescribers: the patients most in need of the medication are the ones most likely to drink on top of it, and that combination is more dangerous than either substance alone. Monitoring for co-ingestion of other depressants is considered essential during treatment.15PubMed. Toxicological considerations in the prescription of baclofen for the treatment of substance use disorders
Withdrawal and Overdose Risks
Stopping baclofen abruptly after chronic use can trigger a withdrawal syndrome that looks a lot like alcohol or benzodiazepine withdrawal, including delirium. Case reviews have found that baclofen-withdrawal delirium is hard to distinguish from delirium caused by other conditions, and when it goes unrecognized, it carries significant risk of serious harm.16PubMed. Delirium associated with baclofen withdrawal: a review of common presentations and management strategies The risk appears higher in people who have been on baclofen for a long time and at higher doses. Tapering slowly rather than stopping all at once is standard practice.
Intentional overdose is another concern, especially in a population with elevated rates of depression and suicidality. Large ingestions of baclofen cause central nervous system depression, seizures, cardiac conduction abnormalities, low blood pressure, and slowed heart rate. The drug’s half-life can extend to 12 to 36 hours after an overdose, and impaired kidney function delays clearance further. Fatal intoxications have been documented at blood levels around 6 to 10 milligrams per liter.17PubMed Central. How to Manage Self-Poisoning With Baclofen in Alcohol Use Disorder? Current Updates Life-threatening toxicity and withdrawal are both recognized complications of baclofen therapy.18PubMed Central. Baclofen therapeutics, toxicity, and withdrawal: A narrative review
How Baclofen Compares to Approved Medications
Head-to-head trials between baclofen and the approved medications are scarce, but the limited data suggest baclofen is not clearly superior. A comparative study measuring craving and relapse warning signs found that naltrexone produced the largest reductions in compulsive drinking scores and relapse risk scores, followed by baclofen and then acamprosate.19PubMed Central. A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence That ordering is roughly what you would expect from the broader literature on naltrexone, which has the strongest evidence base of any alcohol medication. Baclofen’s advantage lies not in outperforming these drugs on average but in being usable when they are not, particularly in the liver disease population discussed earlier.
When added to standard psychosocial treatment, baclofen has not always shown additional benefit over therapy alone. A year-long randomized trial found no difference in heavy drinking or abstinent days between baclofen plus psychosocial support and placebo plus the same support, though both groups improved substantially on craving, depression, and quality of life.20PubMed. Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up That result is a reminder that good psychosocial care is the backbone of treatment for alcohol use disorder, and any medication works alongside it rather than replacing it.
Baclofen During Alcohol Withdrawal
Beyond its use for long-term craving control, baclofen has been studied as a treatment for the acute withdrawal syndrome that occurs when a heavy drinker suddenly stops. A randomized trial comparing baclofen to diazepam (a standard benzodiazepine) for uncomplicated alcohol withdrawal found that both drugs significantly reduced withdrawal symptom scores, with no meaningful difference between them on sweating, tremors, or anxiety. Diazepam was slightly faster at reducing agitation, but overall the two treatments performed comparably.21The American Journal of Medicine. Baclofen Compared With Diazepam in the Treatment of Alcohol Withdrawal Syndrome: A Randomized Clinical Study
More recently, a combination of gabapentin and baclofen was evaluated as an alternative to benzodiazepines for inpatient withdrawal management. Patients treated with the combination had a significantly shorter average hospital stay, roughly 43 hours compared to about 83 hours in the benzodiazepine group, with comparable safety outcomes and no seizures or delirium tremens in the gabapentin/baclofen arm.22PubMed Central. Evaluation of Gabapentin and Baclofen Combination for Inpatient Management of Alcohol Withdrawal Syndrome These findings are preliminary, but they point toward potential uses of baclofen that go beyond the relapse-prevention role most trials have focused on.
Where Baclofen Is Actually Used
France is the only country that has granted baclofen formal regulatory approval for alcohol use disorder, and even there the approval has been contested and revised over the years. Outside France, baclofen is used off-label for this purpose, primarily in some European countries and in Australia, typically for patients who have not responded to or cannot tolerate the approved medications.23PubMed Central. The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective Clinicians who prescribe it are expected to inform patients that the use is off-label, that no optimal dose has been established, and that the clinical evidence is inconsistent. Following the updated Cochrane review and growing evidence in liver disease patients, baclofen has been incorporated into some international treatment guidelines, particularly for alcohol-related liver disease.24PubMed Central. Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis – Section: Discussion
From a cost perspective, both baclofen and the approved medications appear to be cost-saving compared to no pharmacological treatment in patients with alcohol-related cirrhosis, meaning the healthcare savings from reduced liver disease progression outweigh the cost of the medication itself.25PubMed Central. Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis The drug itself is inexpensive and available as a generic, which partly explains its grassroots popularity among patients and some prescribers even without formal approval.
Kidney Function Matters
Because baclofen is primarily cleared through the kidneys, impaired kidney function can cause the drug to accumulate to dangerous levels. Case reports have documented encephalopathy, a state of severe confusion and reduced consciousness, in patients with chronic kidney disease who took baclofen at what would normally be considered trivial doses. In one series, two patients developed encephalopathy within six to eight hours of taking a single tablet, and a third developed it after just four days on 2.5 milligrams twice daily. All three recovered fully after hemodialysis.26PubMed Central. Baclofen-induced neurotoxicity in chronic kidney disease: Is there a safe dose? These cases are a sharp reminder that the drug’s favorable liver safety profile can lull prescribers into overlooking kidney function, which needs to be checked before starting treatment and monitored if it changes.
What Happens to Craving in Practice
One of the most consistent findings across baclofen studies, even the ones that fail on their primary outcome, is a reduction in self-reported craving. A chart review of patients treated with 20 to 40 milligrams per day of baclofen found that 70 percent reported severe and persistent craving at baseline, but only 15 percent still reported it after four weeks.27PubMed Central. Clinical experience of baclofen in alcohol dependence: A chart review That drop is large enough to be clinically relevant for the individual, even if group-level outcomes in controlled trials often do not reach statistical significance because craving reduction does not always translate neatly into fewer drinking days in every patient. For the subset of people whose drinking is heavily driven by cravings rather than social habit or environmental triggers, this effect may be the mechanism through which baclofen actually helps.
Ameisen, whose self-experiment started the whole baclofen-for-alcohol conversation, described complete suppression of both craving and anxiety at high doses.28PubMed. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician His case remains influential despite being a single anecdote, in part because it resonated with the lived experience of many patients who found that approved medications did little for their cravings. The gap between that anecdotal enthusiasm and the modest average effects seen in controlled trials is the central tension in the baclofen story, and it likely reflects genuine biological variation in who responds, rather than either side being simply wrong.